Abstracts tagged "PAD"

Abstract Number: 77 • 2018 ACR/ARHP Annual Meeting
Single Nucleotide Polymorphism in the Gene Encoding Peptidylarginine Deiminase 4 Correlates with Reduced Neutrophil Extracellular Traps and Anti-Histone Antibodies in Rheumatoid Arthritis
Aisha M. Mergaert¹, Mandar Bawadekar², Thai Q. Nguyen¹, Steven J. Schrodi^3,4 and Miriam A. Shelef^2,5, ¹University of Wisconsin - Madison, Madison, WI, ²Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ³Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, ⁴Computation and Informatics in Biology and Medicine, University of Wisconsin - Madison, Madison, WI, ⁵William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: In neutrophils, peptidylarginine deiminase 4 (PAD4) citrullinates histones allowing chromatin unraveling and neutrophil extracellular trap (NET) formation. NETs are increased and display proteins targeted…
Abstract Number: 1461 • 2018 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase-4 Antibodies Are Not Associated with Worse RA Activity, Symptoms or Impacts
Dana DiRenzo¹, Erika Darrah², Susan J. Bartlett^3,4, Clifton O. Bingham III⁴ and Laura C. Cappelli¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antibodies to peptidylarginine deiminase (PAD) enzymes have been implicated in the pathogenesis of RA. Previous studies have shown that patients with PAD4 antibodies…
Abstract Number: 1471 • 2018 ACR/ARHP Annual Meeting
ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients
Natalia Regine de Franca Shimabukuro^1,2, Maximilien Lora¹, Mariana Useche³, Zhijie Zhou⁴, Joyce Rauch⁵, Luis Eduardo Coelho Andrade², Henri Menard¹ and Ines Colmegna⁶, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Federal University of São Paulo, São Paulo, Brazil, ³Medicine, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Aurora Medical Centre, Oshkosh, WI, ⁵Division of Rheumatology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁶The Research Institute of the McGill University Health Centre, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada
Background/Purpose: Anti-citrullinated protein/peptide autoantibodies (ACPAs) define a major subset of rheumatoid arthritis (RA) patients. Cyclic citrullinated peptides (CCP) are commonly used as the antigen for…
Abstract Number: 2056 • 2018 ACR/ARHP Annual Meeting
Citrullination Is Not a Determinant in the Lack of Tolerance to Peptidylarginine Deiminase 2 and 4 in Rheumatoid Arthritis
Pooja Naik¹, Ryan Davis², Jon T. Giles³, Felipe Andrade⁴ and Erika Darrah⁵, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Columbia University, New York, NY, ⁴Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Peptidylarginine deiminase (PAD) 2 and 4 are targets of the humoral response in RA. However, the mechanisms by which these enzymes become immunogenic in…
Abstract Number: 2794 • 2018 ACR/ARHP Annual Meeting
Peptidylarginine Deiminases Are Required for Normal Immunoglobulin G Half-Life
Mandar Bawadekar¹ and Miriam A. Shelef^1,2, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ²William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: Antibodies are a cornerstone of immunity and pathologic in autoimmunity. Immunoglobulin G (IgG) can undergo multiple different post-translation modifications, some of which can alter…
Abstract Number: 1363 • 2017 ACR/ARHP Annual Meeting
Disease Duration and Shared Epitope, but Not Smoking History, Are Associated with Peptidylarginine Deiminase 4-Antibody Development in Rheumatoid Arthritis
Laura Cappelli¹, Maximilian Konig¹, Pooja Naik², Arvin Saleh³, Allan C. Gelber³, Clifton O. Bingham III⁴ and Erika Darrah⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Clinical characteristics and biomarkers help clinicians predict disease features in rheumatoid arthritis (RA). Both peptidylarginine deiminase 4 (PAD4) antibodies and smoking have been associated…
Abstract Number: 2430 • 2017 ACR/ARHP Annual Meeting
For Each HLA-DRB1 Genotype, the Likelihood to Develop RA Correlates with the Probability of Binding at Least a Peptide from PAD4
Isabelle Auger¹, Nathalie Balandraud² and Jean Roudier³, ¹INSERM UMRs 1097, Marseille, France, ²Rheumatology, APHM, Marseilles, France, ³Arthrites auto-immunes, INSERM UMRs 1097, Marseille, France
HLA-DRB1 genotypic risk to develop ACPA positive RA correlates with capability of encoded HLA-DRB1 chains to bind Peptidyl Arginyl Deiminase (PAD4) peptides, not citrullinated Fibrinogen…
Abstract Number: 483 • 2017 ACR/ARHP Annual Meeting
Anti-Peptidylarginine Deiminase-4 Antibodies Are Present in the Sputum of RA Patients and Can Activate Peptidylarginine Deiminase-4 Enzyme Activity
M. Kristen Demoruelle¹, Hong Wang², Ryan L. Davis², A. Itzam Marin¹, Jill M. Norris³, V. Michael Holers¹, Kevin D. Deane¹ and Erika Darrah², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, The Johns Hopkins University, Baltimore, MD, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: Anti-peptidylarginine deiminase (PAD)-4 antibodies (Abs) are present in a portion of RA patients and associate with more severe joint disease, suggesting that they play…
Abstract Number: 1072 • 2017 ACR/ARHP Annual Meeting
Mutated Peptidylarginine Deiminase from Porphyromonas Gingivalis Is a Target in Rheumatoid Arthritis and Citrullinates Major RA-Autoantigens
Madeleine Jenning¹, Bianka Marklein¹, Jimmy Ytterberg², Gerd R. Burmester¹ and Karl Skriner¹, ¹Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Previous reports showed that peptidylarginine deiminase (PPAD) form Porphyromonas gingivalis (P.g.) is not able to citrullinate proteins internally. Mutated PPAD (mPPAD) from P.g. involved…
Abstract Number: 470 • 2016 ACR/ARHP Annual Meeting
Crucial Involvement of Citrullinated Proteins and ACPA in the Development of Peptide-Glucose-6-Phosphate Isomerase Induced Arthritis
Hoshimi Kawaguchi¹, Isao Matsumoto¹, Hiroshi Ebe¹, Naoto Umeda¹, Yuya Kondo¹, Hiroto Tsuboi² and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Division of Clinical Immunology, Doctoral Programs in Clinical Science, Graduated School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Various citrullinated proteins and anti-citrullinated protein antibodies (ACPA) are increased in patients with rheumatoid arthritis (RA). ACPA have high specificity for RA, and are…
Abstract Number: 570 • 2016 ACR/ARHP Annual Meeting
A Molecular Timeline for Preclinical RA Pathogenesis Defined By Dysregulated PTPN22, Hypercitrullination, and Aberrant Cytokine/Metabolic Profiles in PBMC of at-Risk Individuals
Hui-Hsin Chang¹, Nishant Dwivedi², Bo Sun², Deepak A. Rao³, Jeffrey A. Sparks³, Jennifer Kinslow⁴, Yuko Okamoto⁴, Kevin D. Deane⁵, M. Kristen Demoruelle⁶, Jill M. Norris⁷, Elizabeth Karlson², V. Michael Holers⁸ and I-Cheng Ho¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁷Epidemiology, Colorado School of Public Health, Aurora, CO, ⁸Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: One unique feature of RA is the presence of ACPA. PTPN22 is a phosphatase that also acts to suppress citrullination independently of its phosphatase…
Abstract Number: 1116 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibodies Promote Synovial Fibroblasts Migration and Adhesion through a Peptidylarginine Deiminases (PAD) Dependent Pathway
Meng Sun¹, Vijay Joshua¹, Akilan Krishnamurthy¹, Yanying Liu², Aase Hensvold¹, Sergiu-Bogdan Catrina³, Caroline Ospelt⁴, Vivianne Malmström⁵, Khaled Amara¹, Johanna Steen¹, Muhammad Sohel Mia¹, Marianne Engström¹, Heidi Wähämaa¹, Jimmy Ytterberg¹, Bence Rethi¹ and Anca I Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Peking University People's Hospital, Beijing, China, ³Molecular Medicine and Surgery, Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴University Hospital Zurich, Center of Experimental Rheumatology, Switzerland, Zurich, Switzerland, ⁵Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Synovial fibroblasts (SFs) contribute to rheumatoid arthritis (RA) pathogenesis by growing into the synovial space and by producing pro-angiogenic and tissue remodelling factors, chemokines…
Abstract Number: 3022 • 2016 ACR/ARHP Annual Meeting
Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis
Erika Darrah¹, Jon T. Giles², Ryan Davis¹, Pooja Naik¹, Maximilian Konig¹ and Felipe Andrade¹, ¹Department of Medicine, Division of Rheumatology, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ²Columbia University, College of Physicians and Surgeons, Division of Rheumatology, New York, NY
Background/Purpose: The mechanisms that drive clinical heterogeneity and outcomes in patients with rheumatoid arthritis (RA) are poorly understood, but precise biomarkers may identify clinically unique…
Abstract Number: 3148 • 2016 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation
Mandar Bawadekar¹, Daeun Shim¹, Ryan Rebernick¹, Chloe Peyton¹, Chad J. Johnson², Thomas F. Warner³, Dres Damgaard⁴, Claus Henrik Nielsen⁵, Anthony P. Nicholas⁶, Ger JM Pruijn⁷, Jeniel E. Nett⁸ and Miriam A. Shelef^1,9, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison, Madison, WI, ²Department of Medicine, University of Wisconsin-Madison, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, ⁴Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁵Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁶Neurology, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, ⁷Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands, ⁸Medicine and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, ⁹William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The presence of anti-citrullinated protein antibodies in rheumatoid arthritis points to a potential role for citrullination in disease pathogenesis. Peptidylarginine deiminases (PADs) catalyze the…
Abstract Number: 527 • 2015 ACR/ARHP Annual Meeting
Characterisation of the Antibody Response to a Citrullinated Peptide – Derived from the Porphyromonas Gingivalis Peptidyl Arginine Deiminase Enzyme – in Patients with Rheumatoid Arthritis
Nastya Kharlamova¹, Xia Jiang², Natalia Sherina³, Monika Hansson⁴, K. Lundberg⁵ and Lars Alfredsson⁶, ¹Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, ²Rheumatology, karolinska institutet, skärholmen, Sweden, ³Rheumatology, karolinska institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institute, Stockholm, Sweden, ⁶The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: It has been hypothesized that Porphyromonas gingivalis - the only known pathogen to express a citrullinating enzyme (called P.PAD) - is etiologically linked to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].